Research and Markets (http://www.researchandmarkets.com/research/4f6tmn/global_orphan) has announced the addition of the "Global Orphan Drug Pipeline & Regulatory Insight 2015" report to their offering.

Owing to the pharmaceutical companies' inadequate interest in this category of drugs, the term orphan was coined for drugs targeted to treat rare diseases. Almost 222 orphan designated drugs in US and 132 in Europe are marketed till date. However, in spite of the increased efforts in this market, there is still a shortage in the number of treatments for most rare disease indications. Thus, the market for rare diseases in the United States, Europe and other regions continue to offer significant potential for growth owing to enormous unmet medical need.

The US and European region are the major markets for orphan drugs. It is in these two regions that the popularity of these drugs and diseases is increasing rapidly. The US alone accounts for a dominating share of 55%-60% in the global pie, followed by Europe. As the Asian pharmaceutical markets are still in nascent stage, there opportunities for orphan drugs in Asia are also immense and getting increasingly popular. It is expected that by 2017-18, the Asian orphan drugs market would witness steady growth.

Global Orphan Drug Pipeline & Regulatory Insight 2015 Report Highlights & Findings:

  • Europe Orphan Drug Clinical Pipeline: 697 Drugs
  • Majority Orphan Designated Drugs in Phase-II : 249
  • Globally Marketed Orphan Drugs: 274

Key Topics Covered:

1. What Are Orphan Drugs?

2. Global Orphan Drug Market Outlook

3. Orphan Drug Designation Criteria

4. Reimbursement Policy For Orphan Drug

5. US (FDA) Regulatory Framework For Orphan Drugs

6. Europe (EMA) Regulatory Framework For Orphan Drugs

7. Asia Regulatory Framework For Orphan Drugs

8. Global Orphan Drug Pipeline by Company, Country, Indication & Phase

9. Marketed Orphan Drug by Company, Country & Indication

10. Discontinued & Suspended Orphan Drugs in Clinical Trials

11. Competitive Landscape

  • AOP Orphan
  • Agenus
  • Alexion
  • Bristol Myers Squibb
  • Biogen Idec
  • Celgene
  • Eli Lilly
  • Genethon
  • Genzyme Corporation
  • Glaxosmithkline
  • Merck
  • Novartis Pharmaceuticals
  • Orphan Europe
  • Pfizer
  • Prosensa
  • Rare Disease Therapeutics
  • Roche
  • Sanofi
  • Shire
  • Teva Pharmaceutical

For more information visit http://www.researchandmarkets.com/research/4f6tmn/global_orphan